GRM6

Across TCGA pan-cancer cohorts, GRM6 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of GRM6’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where GRM6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GRM6 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where GRM6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRM6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.864	<.001	8	view →
HNSC	Male	All	−0.613	<.001	8	view →
LSCC	All	II,III,IV	−1.231	<.001	7	view →
PDAC	Female	All	+0.466	.024	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

GRM6–LUAD

Open the LUAD breakdown →